review Open AccessTop 1% cited
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Oncogene · 2009 · Vol. 28(S1) · pp. S24–S31
Adi F. Gazdar✉(The University of Texas Southwestern Medical Center)
Lung Cancer Treatments and MutationsCancer therapeutics and mechanismsHER2/EGFR in Cancer ResearchGefitinibErlotinibT790MBiologyCancer researchTyrosine kinaseAfatinibEpidermal growth factor receptorERBB3Point mutation
MeSH terms
Erlotinib HydrochlorideGefitinibCarcinoma, Non-Small-Cell LungGene AmplificationHumansLung NeoplasmsProto-Oncogene ProteinsQuinazolinesProto-Oncogene Proteins p21(ras)Treatment OutcomePoint MutationSequence DeletionProtein Structure, TertiaryReceptors, Growth Factorras Proteins
Funding
- Boehringer Ingelheim
- National Cancer Institute
Citations
979
FWCI
37.76
field-weighted impact
References
54
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting RTK Signaling Pathways in Cancer
Cancers · 2015 · 375 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Cell death-based treatment of lung adenocarcinoma
Cell Death and Disease · 2018 · 781 citations
CircRNAs: role in human diseases and potential use as biomarkers
Cell Death and Disease · 2021 · 369 citations
References
Epidermal growth factor receptor mutations in lung cancer
Nature reviews. Cancer · 2007 · 3,115 citations
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
International Journal of Cancer · 2005 · 661 citations
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
JNCI Journal of the National Cancer Institute · 2005 · 1,568 citations
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
PLoS Medicine · 2005 · 3,519 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Oncogene · 2008 · 1,434 citations
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Clinical Cancer Research · 2006 · 827 citations
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
PLoS Medicine · 2005 · 1,521 citations
Related articles
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.